A strategic framework for novel drug development in multiple myeloma.
作者信息
Anderson Kenneth C, Hannah Alison L, Pazdur Richard, Farrell Ann T
机构信息
Department of Medicine, Harvard Medical School, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
出版信息
Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.
Abstract
摘要
相似文献
1
A strategic framework for novel drug development in multiple myeloma.
Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.
2
[Methodological approaches of clinical studies with targeted therapies].
Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575.
3
Developing drugs that do not cause tumor regression.
Clin Adv Hematol Oncol. 2003 Nov;1(11):654-5.
4
Design and endpoints of clinical trials in hepatocellular carcinoma.
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.
5
Randomized phase II trials: misleading and unreliable.
J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.
6
Clinical trials.
Methods Mol Med. 2003;87:335-52. doi: 10.1385/1-59259-399-2:335.
7
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Clin Cancer Res. 2005 Aug 1;11(15):5342-6. doi: 10.1158/1078-0432.CCR-05-0458.
8
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057.
9
[Phase III trials in oncology].
Bull Cancer. 1999 Feb;86(2):143-7.
10
Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
J Natl Cancer Inst. 2008 Nov 5;100(21):1557; author reply 1557-8. doi: 10.1093/jnci/djn341. Epub 2008 Oct 28.
引用本文的文献
1
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
Br J Cancer. 2013 Mar 19;108(5):1061-70. doi: 10.1038/bjc.2013.74. Epub 2013 Feb 28.
2
Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.
J Pathol. 2010 Jul;221(3):242-7. doi: 10.1002/path.2714.
3
IL-6 and MYC collaborate in plasma cell tumor formation in mice.
Blood. 2010 Mar 4;115(9):1746-54. doi: 10.1182/blood-2009-08-237941. Epub 2009 Dec 17.
Zotero 插件